P
Panaxia Labs Israel Ltd
TASE:PNAX
Panaxia Labs Israel Ltd
TASE:PNAX
Price:
5 192
ILS
-1.05%
Market Closed
Market Cap:
₪7.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
P
|
Panaxia Labs Israel Ltd
TASE:PNAX
|
IL |
|
Grauer And Weil (India) Ltd
NSE:GRAUWEIL
|
IN |
|
ARMOUR Residential REIT Inc
F:2AR1
|
US |
|
I
|
iPeople Inc
XPHS:IPO
|
PH |
|
A
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
US |
|
L
|
Lastminute.com NV
SIX:LMN
|
NL |
|
T
|
TLB Co Ltd
KOSDAQ:356860
|
KR |
|
M
|
Medtronic PLC
F:2M6
|
IE |
|
K
|
Kekrops SA
ATHEX:KEKR
|
GR |
|
Talon Energy Ltd
ASX:TPD
|
AU |
|
G
|
Great Water Holdings Ltd
HKEX:8196
|
CN |
|
Samsonite International SA
HKEX:1910
|
LU |
|
T
|
Third Harmonic Bio Inc
NASDAQ:THRD
|
US |
|
Defentect Group Inc
OTC:DFTC
|
US |
|
IDT Corp
NYSE:IDT
|
US |
|
Fujian Sanmu Group Co Ltd
SZSE:000632
|
CN |
|
Midea Real Estate Holding Ltd
HKEX:3990
|
CN |
|
Elanor Commercial Property Fund
ASX:ECF
|
AU |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of PNAX.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PNAX
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
PNAX Competitors Multiples
Panaxia Labs Israel Ltd Competitors
Panaxia Labs Israel Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
P
|
Panaxia Labs Israel Ltd
TASE:PNAX
|
7.9m ILS | 0.3 | -0.3 | -1.8 | -1.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879.7B USD | 13.9 | 43.8 | 29.5 | 31.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.1B USD | 6.1 | 21.5 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.2 | 11.4 | 12.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.2B USD | 4.7 | 16.6 | 10.3 | 12.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF | 5.2 | 20.8 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.9 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.1B USD | 2.5 | 16.8 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
